Methylphenidate
DAT/NET inhibitor stimulant, ADHD first-line Rx (Novartis Ritalin, Janssen Concerta). DEA Schedule II, significant abuse potential.
WHAT IS METHYLPHENIDATE?
Detailed overview
Methylphenidate is a psychostimulant synthesized in 1944, approved in 1954 for child hyperactivity, since 1990s the first-line ADHD treatment. DAT and NET reuptake inhibition raises synaptic dopamine and norepinephrine in prefrontal cortex, improving executive function (attention, impulse control, working memory) in ADHD. DEA Schedule II (USA), with corresponding Rx tightening. IR (Ritalin, 3-5 h) and ER/OROS (Concerta 10-12 h) forms. MTA trial (1999 JAMA, 14-month follow-up) showed stimulant + behavioral therapy combination superior. Abuse potential: crushed-inhaled or IV-injected produces amphetamine-like euphoria, hence XR forms preferred.
Data console
Lab data
Safety
Side effects, stop signs, contraindications
Side effects · 8
- Cardiovascular effects: increased heart rate, modest blood pressure rise, palpitations. Boxed-warning-level concern: risk of sudden death, stroke and myocardial infarction in people with structural cardiac abnormalities or serious heart disease, especially with misuse.
- Dependence and abuse (Schedule II): chronic use carries risk of tolerance, psychological dependence and withdrawal; crushed-insufflated or injected use produces amphetamine-like euphoria and high abuse potential.
- Psychiatric effects: anxiety, irritability, mood lability; rarely new treatment-emergent psychotic or manic symptoms (hallucinations, paranoia) even without prior history, plus aggression and hostility.
- Decreased appetite (~30%) and weight loss; in children a transient slowing of growth (height and weight), so regular growth monitoring is required.
- Insomnia and sleep disturbance, especially with late-afternoon or evening dosing (avoid after 4 PM); headache, dizziness, dry mouth.
- Peripheral vascular effects: Raynaud phenomenon and peripheral vasospasm, rarely digital ischemia with chronic use; discoloration of fingers should be reported.
- Priapism: rare but urological emergency involving prolonged, painful erection, requiring immediate care to prevent lasting tissue damage.
- Onset or worsening of motor and vocal tics; rarely serotonin syndrome when combined with serotonergic drugs (e.g. MAO inhibitors).
Contraindications · 4
- MAOi within 14 days (hypertensive crisis)
- Severe CV disease (LV hypertrophy, severe hypertension, coronary insufficiency)
- Hyperthyroidism, angle-closure glaucoma
- Active substance dependence, psychotic symptom history (relative)
Related Pharmaceuticals
Same therapeutic category
Studies
Related research and clinical findings
A 14-month randomized clinical trial of treatment strategies for ADHD (MTA Cooperative Group)
MTA Cooperative Group.
Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Storebø OJ, Pedersen N, Ramstad E et al.
Attention-deficit hyperactivity disorder, multimodal treatment, and longitudinal outcome: evidence, paradox, and challenge.
Hinshaw SP, Arnold LE, MTA Cooperative Group
Telegram
Have a question about Methylphenidate?
Educational drug info from official sources (PubMed, FDA, EMA). Does NOT replace medical consultation or the SmPC. Talk to your doctor!
The information here is for educational and scientific purposes only. Medication use requires medical consultation and a prescription. The indications, dose ranges, and side effects listed here do NOT replace the official Summary of Product Characteristics (SmPC) or consultation with a physician. Do not start or stop any medication on your own. In an emergency, call your local emergency number.